BCDA

Altman Peter

Known title: President and CEOCIK: 0001647542

Altman Peter's purchase track record

How the stock did after each of Altman Peter's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
35
of 46 since November 18, 2021
Stock higher 6 months later
26%
3 months: 45%
Median 6-month return
-25.0%
3 months: -1.5%
Beat the S&P 500
29%
median -34.3% vs. index
PurchaseStockAmount3 months6 months
9/23/2026BCDA$3Kpendingpending
9/3/2026BCDA$872pendingpending
8/13/2026BCDA$7Kpendingpending
7/29/2026BCDA$4Kpendingpending
7/17/2026BCDA$415+10.8%pending
7/8/2026BCDA$16K+12.4%pending
6/17/2026BCDA$2K+31.6%pending
6/9/2026BCDA$4K+29.1%pending
5/15/2026BCDA$12K-4.0%pending
4/29/2026BCDA$6K-30.0%pending
4/20/2026BCDA$1K-28.0%pending
3/24/2026BCDA$1K-17.4%-12.0%
2/4/2026BCDA$6K+1.8%-12.8%
1/20/2026BCDA$1K-7.7%-29.2%
12/16/2025BCDA$1K0.0%-32.0%
9/19/2025BCDA$60K+9.5%+3.5%
8/22/2025BCDA$1K-28.3%-40.8%
8/11/2025BCDA$4K-23.2%-25.0%
6/30/2025BCDA$50K-28.2%-36.9%
5/30/2025BCDA$221-8.3%-32.9%
5/22/2025BCDA$1K-4.7%-32.6%
5/14/2025BCDA$4K-32.9%-53.1%
4/23/2025BCDA$50K+29.0%-21.5%
4/10/2025BCDA$1K+25.4%-28.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.

this person other insiders at BCDA

Transaction History

BCDA▲ Buy$1K
BCDA▲ Buy$2K
BCDA▲ Buy$872
BCDA▲ Buy$5K
BCDA▲ Buy$2K
BCDA▲ Buy$4K
BCDA▲ Buy$415
BCDA▲ Buy$1K
BCDA▲ Buy$2K
BCDA▲ Buy$940
BCDA▲ Buy$900
BCDA▲ Buy$5K
BCDA▲ Buy$5K
BCDA▼ Sell$68K
BCDA▲ Buy$133K
BCDA▲ Buy$768
BCDA▲ Buy$1K
BCDA▲ Buy$4K
BCDA▲ Buy$1K
BCDA▲ Buy$190
BCDA▲ Buy$5K
BCDA▲ Buy$5K
BCDA▲ Buy$6K
BCDA▲ Buy$492
BCDA▲ Buy$738
BCDA▲ Buy$366
BCDA▲ Buy$744
BCDA▲ Buy$6K
BCDA▲ Buy$402
BCDA▲ Buy$792
BCDA▲ Buy$1K
BCDA▲ Buy$274
BCDA▲ Buy$146K
BCDA▼ Sell$77K
BCDA▲ Buy$60K
BCDA▲ Buy$1K
BCDA▲ Buy$183
BCDA▲ Buy$700
BCDA▲ Buy$3K
BCDA▲ Buy$50K
BCDA▲ Buy$221
BCDA▲ Buy$1K
BCDA▲ Buy$3K
BCDA▲ Buy$730
BCDA▲ Buy$299
BCDA▲ Buy$50K
BCDA▲ Buy$214
BCDA▲ Buy$609
BCDA▲ Buy$597
BCDA▲ Buy$980
BCDA▲ Buy$2K
BCDA▲ Buy$1K
BCDA▲ Buy$3K
BCDA▲ Buy$1K
BCDA▲ Buy$1K
BCDA▲ Buy$1K
BCDA▲ Buy$569
BCDA▲ Buy$1K
BCDA▲ Buy$2K
BCDA▲ Buy$555
BCDA▲ Buy$3K
BCDA▲ Buy$117K
BCDA▼ Sell$57K
BCDA▲ Buy$125K
BCDA▲ Buy$915
BCDA▲ Buy$598
BCDA▲ Buy$2K
BCDA▲ Buy$2K
BCDA▲ Buy$3K
BCDA▲ Buy$1K
BCDA▲ Buy$195
BCDA▲ Buy$50K
BCDA▲ Buy$3K
BCDA▲ Buy$4K
BCDA▲ Buy$15K
BCDA▼ Sell$65K
BCDA▲ Buy$10K
BCDA▲ Buy$186K
BCDA▲ Buy$25K
BCDA▲ Buy$3K
BCDA▲ Buy$6K
BCDA▲ Buy$3K
BCDA▲ Buy$6K
BCDA▲ Buy$5K
BCDA▲ Buy$7K
BCDA▲ Buy$4K
BCDA▲ Buy$14K
BCDA▼ Sell$42K
BCDA▲ Buy$1K
BCDA▲ Buy$4K
BCDA▲ Buy$4K
BCDA▲ Buy$19K
BCDA▲ Buy$0
BCDA▲ Buy$187
BCDA▲ Buy$11K

We use analytics to understand how market-wall is used. No personal data is sold.